Target intelligence / Profile preview

Aryl hydrocarbon receptor nuclear translocator (ARNT) (ARNT)

Target
ARNT
Molecular classification
Transcription factor
01

Overview

Aryl hydrocarbon receptor nuclear translocator (ARNT), also known as hypoxia-inducible factor 1-beta (HIF-1β), is a basic helix-loop-helix-PAS transcription factor that serves as an obligate dimerization partner for several key transcription factors, including HIF-1α, HIF-2α, and the aryl hydrocarbon receptor (AhR). In response to hypoxia or environmental toxins, ARNT forms active heterodimeric complexes that translocate to the nucleus and bind to specific DNA response elements, driving the transcription of genes involved in angiogenesis, glycolysis, cell survival, and xenobiotic metabolism. In clear cell renal cell carcinoma (ccRCC), loss of the von Hippel-Lindau (VHL) tumor suppressor leads to constitutive activation of the HIF pathway, making ARNT a critical therapeutic target. Historically considered difficult to target with small molecules due to its role as a transcription factor scaffold, ARNT is now being targeted by novel therapeutics such as NEO-811, a clinical-stage molecular glue degrader that recruits the CRL4-CRBN E3 ubiquitin ligase to induce proteasomal degradation of ARNT, thereby comprehensively shutting down oncogenic HIF and AhR signaling.

Other names
Hypoxia-inducible factor 1-betaHIF-1-betaHIF-1βHIF1BTANGOClass E basic helix-loop-helix protein 2bHLHe2
02

Mechanism of action

Targeted protein degradation via cereblon-mediated ubiquitination and proteasomal degradation

03

Biological functions

Transcription regulationResponse to hypoxiaXenobiotic metabolismAngiogenesisCellular adaptation to stress
04

Disease associations

CancerRenal cell carcinomaType 2 diabetes
05

Safety considerations

Teratogenicity (due to cereblon binding)Systemic toxicity from broad HIF pathway inhibitionImpaired physiological response to hypoxiaAltered xenobiotic metabolism
06

Interacting drugs

07

Biomarkers

ARNT expression levelVHL mutation statusHIF-2α mutation status (e.g., G323E)VEGF expression level

Beyond the preview

Go deeper on Aryl hydrocarbon receptor nuclear translocator (ARNT) (ARNT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aryl hydrocarbon receptor nuclear translocator (ARNT) (ARNT).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call